Literature DB >> 678426

A tumour-associated antigen from the pleural effusion of patients with squamous-cell carcinoma of lung.

A Wolf.   

Abstract

A fraction showing tumour-associated antigenic properties has been isolated from pleural effusions of patients with squamous-cell carcinoma of the lung. Purification of the material was accomplished by ion-exchange and affinity chromatography, and by immunoabsorbents. The antigenic activity was monitored by its inhibitory capacity in a specific complement-dependent cytotoxic system. The final fraction has a mol. wt. of approximately 1.7 X 10(5), as judged by gel filtration on Sephadex G200, and the main component appears to be a glycoprotein with N-acetyl-D-glucosamine groups. The most purified antigen preparation exhibited a highly selective capacity to inhibit in the cytotoxic assay and to bind, when labelled with 125I, to 2 specific antisera. The active fractions isolated from pleural effusions fully crossreacted with fractions prepared from squamous-cell carcinoma extracts. CEA and bacterial antigens were not detected in the material, and the presence of alpha-fetoprotein, HLA and blood-group antigens may be ruled out on account of their respective molecular weights.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 678426      PMCID: PMC2009660          DOI: 10.1038/bjc.1978.152

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Reactivity of lung cancer patients in leukocyte migration inhibition assays to 3-M potassium chloride extracts of fresh tumor and tissue-cultured cells derived from lung cancer.

Authors:  J L McCoy; L F Jerome; G B Cannon; J L Weese; R B Herberman
Journal:  J Natl Cancer Inst       Date:  1977-11       Impact factor: 13.506

2.  Immunologic studies of glycoproteins isolated from cell membranes of human lung carcinomas.

Authors:  T W Tillack; J Rosai; D J Vervynck
Journal:  J Natl Cancer Inst       Date:  1974-04       Impact factor: 13.506

3.  Radioimmunoassay and saturation analysis. Preparation and assessment of radioactive tracers.

Authors:  W M Hunter
Journal:  Br Med Bull       Date:  1974-01       Impact factor: 4.291

4.  Water-soluble P-815 mastocytoma membrane antigens: separation of tumour-associated antigens from histocompatibility antigens.

Authors:  K J Clemetson; M Bertschmann; S Widmer; E F Lüscher
Journal:  Immunochemistry       Date:  1976-05

Review 5.  Soluble proteins of human bronchogenic carcinomas.

Authors:  D J Granlund; R E Ritts
Journal:  Mayo Clin Proc       Date:  1976-01       Impact factor: 7.616

6.  Isolation and identification of human lung tumor-associated antigens.

Authors:  R W Veltri; H F Mengoli; P E Maxim; S Westfall; J M Gopo; C W Hauang; P M Sprinkle
Journal:  Cancer Res       Date:  1977-05       Impact factor: 12.701

7.  Separation of a tumour specific transplantation-type antigen from the ascitic fluid of mice bearing a syngeneic lymphoma.

Authors:  A Wolf; K A Steele
Journal:  Br J Cancer       Date:  1975-06       Impact factor: 7.640

8.  Estimation in sera by radioimmunoassay of a specific membrane antigen associated with a murine lymphoma.

Authors:  A Wolf; K A Steele; P Alexander
Journal:  Br J Cancer       Date:  1976-02       Impact factor: 7.640

9.  Evidence for a common tumour-associated antigen in extracts of human bronchogenic carcinoma.

Authors:  B Kelly; J G Levy
Journal:  Br J Cancer       Date:  1977-06       Impact factor: 7.640

10.  Extraction and preliminary characterization of a human bronchogenic carcinoma antigen.

Authors:  M J Frost; G T Rogers; K D Bagshawe
Journal:  Br J Cancer       Date:  1975-04       Impact factor: 7.640

  10 in total
  2 in total

1.  An improved antigenic marker of human lung carcinomas and its use in radioimmunoassays.

Authors:  A Wolf; M Micksche; H Bauer
Journal:  Br J Cancer       Date:  1981-03       Impact factor: 7.640

2.  Collaborative study of bronchial tumour-associated antigens.

Authors:  J N Gennings; K D Bagshawe; N H Axelsen; P Sizaret
Journal:  Br J Cancer       Date:  1981-10       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.